CN-122012341-A - Elephant source bacillus licheniformis and application thereof

Abstract

The invention discloses elephant source bacillus licheniformis and application thereof. A Bacillus licheniformis strain L517 with a accession number GDMCC 67825, a classification of Bacillus licheniformis and a accession date of 2026, 2 and 26 days. The research of the invention shows that the bacillus licheniformis has remarkable treatment effect on the acute colonitis of mice and also has remarkable treatment effect on the subcutaneous colon cancer of mice. The anticancer mechanism is that the supernatant metabolite of the culture medium can obviously promote the infiltration of GZMB+CD8+ cytotoxic T cells in the tumor microenvironment in vivo, and can directly up-regulate tumor suppressor gene P53. The invention discovers for the first time that the elephant intestinal tract-derived bacillus licheniformis with evolution disease resistance advantage shows good activity of resisting proctitis and colon cancer, and can be an effective medicament for treating proctitis and colon cancer in the future.

Inventors

• WANG XIAOYI
• LIU XINGYIN
• ZHANG XUEMEI

Assignees

• 江苏省人民医院（南京医科大学第一附属医院）

Dates

Publication Date

20260512

Application Date

20260320

Claims (8)

1. 1. A bacillus licheniformis strain L517 is characterized by having a preservation number GDMCC 67825, a classification name Bacillus licheniformis and a preservation date of 2026, 2 and 26 days.
2. 2. Use of bacillus licheniformis strain L517 according to claim 1 for the preparation of an antitumor drug.
3. 3. The method according to claim 2, wherein the tumor is colorectal cancer.
4. 4. Use of bacillus licheniformis strain L517 according to claim 1 for the preparation of an anti-inflammatory medicament.
5. 5. The method of claim 4, wherein the anti-inflammatory agent is an anti-colitis agent.
6. 6. The method according to claim 2 to 5, wherein the Bacillus licheniformis strain L517 is a live strain of Escherichia coli, a culture supernatant or a metabolite thereof.
7. 7. The method according to claim 2 to 5, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or a conventional edible excipient.
8. 8. The method according to claim 2 to 5, wherein the pharmaceutical dosage form is an oral dosage form.

Description

Elephant source bacillus licheniformis and application thereof Technical Field The invention belongs to the fields of biological medicine and microorganisms, and particularly relates to application of elephant bacillus licheniformis in preparation of anti-inflammatory or anti-tumor medicines. Background Colorectal cancer (Colorectal cancer, CRC) is one of the gastrointestinal malignancies with the highest morbidity and mortality worldwide, and is a serious public health problem. Although there are many methods of treatment for CRC, such as surgery, chemotherapy, targeted therapy, etc., the prognosis for advanced CRC is still poor, and there are problems of treatment resistance and immune escape. The onset of CRC is a complex multifactorial process in which chronic intestinal inflammation is an important factor in the development of CRC. More and more studies have clarified that intestinal dysbacteriosis and its metabolites have a significant correlation with inflammatory bowel disease and CRC. Elephants have a particular cancer resistance and have traditionally been considered to be associated with multiple copies of the TP53 gene. However, elephant is a herbivore in which a large number of cellulolytic bacteria such as bacillus bacteria are colonized in the intestinal tract. The potential of these commensal flora in maintaining host immunity and cancer resistance is currently not fully exploited. In conclusion, expanding a more effective novel microecological drug against colorectal cancer from the inside of a natural disease-resistant animal body is a technical problem to be solved in the field. Disclosure of Invention The invention aims to provide bacillus licheniformis and application thereof in preparing anti-inflammatory or anti-tumor medicines. In order to achieve the aim, the invention adopts the following technical scheme that the bacillus licheniformis strain L517 has the preservation number of GDMCC 67825, is classified and named Bacillus licheniformis and has the preservation date of 2026, 2 and 26 days. The bacillus licheniformis strain L517 is applied to preparing antitumor drugs. Further, the tumor is colorectal cancer. The bacillus licheniformis strain L517 is applied to the preparation of anti-inflammatory drugs. Further, the anti-inflammatory drug is an anti-colitis drug. Further, the bacillus licheniformis strain L517 is a live strain of elephant bacillus licheniformis, a culture supernatant or a metabolite thereof. Further, the medicine also comprises a pharmaceutically acceptable carrier or conventional edible auxiliary materials. Further, the dosage form of the medicine is an oral dosage form. The research of the invention shows that the elephant bacillus licheniformis has remarkable treatment effect on the acute colonitis of mice, can restore the balance of Th17/Treg cells, has remarkable treatment effect on the colon cancer of mice, and can remarkably increase the infiltration of GZMB+CD8+T cells in the tumor microenvironment. The invention discovers for the first time that the elephant bacillus licheniformis shows good activity of resisting proctitis and colon cancer and can become an effective medicament for treating proctitis and colon cancer in the future. Drawings FIG. 1 is a graph showing the effect of the example acute DSS modeling procedure and Bacillus licheniformis treatment on the modulation of acute colitis phenotype and immune cells. FIG. 2 is a graph showing the effect of example subcutaneous colorectal cancer modeling procedures and Bacillus licheniformis treatment on tumor growth inhibition and immune microenvironment regulation. FIG. 3 is a graph showing the effect of Bacillus licheniformis culture supernatant on induction of colorectal cancer cell apoptosis and upregulation of TP53 expression. Detailed Description In order that those skilled in the art will better understand the present application, a technical solution in the embodiments of the present application will be clearly and completely described below with reference to the accompanying drawings in which it is apparent that the described embodiments are only some embodiments of the present application, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present application without making any inventive effort, shall fall within the scope of the present application. It is noted that the terms "comprises" and "comprising," and any variations thereof, in the description and claims of the present application and in the foregoing figures, are intended to cover a non-exclusive inclusion, such that a process, method, system, article, or apparatus that comprises a list of steps or elements is not necessarily limited to those steps or elements expressly listed or inherent to such process, method, article, or apparatus. Example 1 Bacillus licheniformis treatment was able to ameliorate DSS-induced acute colitis phenotype The modeling process of the a